Covaxin, one of the main vaccines administered to adults in India, is currently being administered to children in the age group of 15-18 years.
The Drugs Controller General of India (DCGI) recommended emergency use authorisation (EUA) for Bharat Biotech’s Covaxin for children between 6-12 years. It is the first vaccine to get EUA nod for this age group.
The subject expert committee (SEC) had suggested amendments to protocols for Covaxin.
Covaxin, one of the main vaccines administered to adults in India, is currently being administered to children in the age group of 15-18 years. The vaccine is administered in two doses, with a gap of 28 days between the first and second doses.
Covaxin was granted emergency use listing by the World Health Organisation on November 3, 2021. This vaccine is a whole virion inactivated vaccine against COVID-19, developed in partnership with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
In January this year, the DCGI gave permission to Bharat Biotech for intranasal COVID booster dose trials BBV154.
